HSPA1A and benign prostatic hyperplasia: In vivo, testosterone‐induced BPH (T‐BPH) rat models treated with the HSPA1A antagonist KNK437 exhibited prostatic atrophy and molecular changes consistent with reduced HSPA1A activity.